menu
    • menu
    [{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"FightMND","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"M102","moa":"Nrf2","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Therapeutics \/ FightMND"},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"Medical Research Council (U.K)","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"M102","moa":"Nrf2","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ Medical Research Council (U.K)","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Therapeutics \/ Medical Research Council (U.K)"}]

    Find Clinical Drug Pipeline Developments & Deals for M102

    Menu

    M102

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aclipse Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Aclipse Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M102

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Medical Research Council (U.K)

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102

                            Details : Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.

                            Brand Name : M102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2021

                            Lead Product(s) : M102

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Medical Research Council (U.K)

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aclipse Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Aclipse Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M102

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : FightMND

                            Deal Size : $0.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND

                            Details : The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.

                            Brand Name : M102

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : M102

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : FightMND

                            Deal Size : $0.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth